You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
Recent awards include:
If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at S&P Capital IQ Pro or S&P Capital IQ .
Abbvie to continue manufacturing component for lymphoma drug
S&P Capital IQ Pro | Powering Your Edge
S&P Capital IQ Pro | Unrivaled Sector Coverage
Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud
Investment Research Analysts Providing Greater Coverage on Inflation
Seattle Genetics Inc. asked AbbVie Inc. to continue manufacturing a component for its Adcetris drug.
The companies extended a development and supply agreement under which AbbVie will manufacture the anti-CD30 monoclonal antibody through Dec. 31, 2025, as opposed to Aug. 22, 2021, previously. The contract will automatically renew unless terminated by either party.
Adcetris is used for the treatment of classical Hodgkin lymphoma, a form of cancer that affects the immune system.